Why carry out this study?

There is a need to better characterize total direct cost after the relapse in patients with MS using the most current data

What did the study ask?

The aim of this study was to evaluate annual cost of relapse by severity of relapse experienced by patients with MS

What were the study outcomes/conclusions?

Overall, this study highlights the cost burden incurred owing to MS relapses. The study provides a more accurate representation of cost burden of relapse (considered as occurrence of the event) using more recent data

What was learned from the study?

The study confirmed that the cost burden drastically increases with the severity of relapse. This underscores the need for high-efficacy therapies which can prevent relapse and progression in patients with multiple sclerosis